As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include interesting publications on pediatric CML.

Read Professor Hughes' CML publications of the month: November 2025

Clinical CML papers

• Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint
  Castagnetti F et al. Leukemia, November 2025 (epub ahead of print) – open access publication
• Successful fatherhood of males with tyrosine kinase inhibitor-resistant chronic myeloid leukemia taking Olverembatinib
  Yu L and Jiang Q. Ann Hematol, November 2025 (epub ahead of print) – open access publication
• Efficacy, safety and predictive biomarker of third-generation tyrosine kinase inhibitors with azacitidine in myeloid blast phase of chronic myeloid leukemia
  Bao M et al. Cancer, November 2025 – open access publication
• Treatment cessation in chronic myeloid leukemia: Evidence and uncertainties - Review
  Mayer J. Hematol Oncol, November 2025 – open access publication
• Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST
  Takahashi N et al. Int J Hematol, November 2025 – open access publication
• Real-world decline in survival with poor guideline adherence in chronic myeloid leukemia care
  Metsemakers SJJPM et al. Blood Cancer J, November 2025 – open access publication
• Hemoglobin changes during long-lasting frontline treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia
  Latagliata R et al. Leuk Lymphoma, November 2025 (epub ahead of print)
• Potential differences between real-life and randomized controlled trial populations in chronic myeloid leukemia
  Horňák T et al. Ann Hematol, November 2025 (epub ahead of print) – open access publication
• Early predictive factors of molecular relapse in chronic-phase chronic myeloid leukemia (CP-CML) patients after tyrosine kinase inhibitor (TKI) discontinuation
  Laganà A et al. Leuk Lymphoma, November 2025 (epub ahead of print)
• Effect of tyrosine kinase inhibitors on sperm parameter and pituitary gonadal axis in males with chronic myeloid leukemia: a prospective cohort study
  Ganju N et al. Leuk Lymphoma, November 2025 (epub ahead of print)
• In-depth analysis for tyrosine kinase inhibitor-driven real-world management of 201 CML patients using TFR
  Micu ML et al. Front Pharmacol, November 2025 – open access publication
• Progression significance for low-level aberrant B-lymphoblasts in chronic myeloid leukemia patients
  Wang H et al. Clin Transl Med, November 2025 – open access publication

Scientific CML papers

• HLA diversity is associated with tyrosine kinase inhibitor response and treatment-free remission in chronic myeloid leukemia
  Toulemonde C et al. Hemasphere, November 2025 – open access publication
• Distinct endothelial cell toxicities of ABL tyrosine kinase inhibitors lead to arterial thrombosis
  Travers R. et al, Blood -  Vessels, Thrombosis & Hemostasis, November 2025 - open access publication

Pediatric CML papers

• Catch-up growth after switch to asciminib in a twin with chronic myeloid leukemia
  Sembill S et al. Lancet, November 2025 (epub ahead of print) – open access publication